10X Fund, L.P. sold GALT
November 11, 2025 · Form 4 insider transaction
10X Fund, L.P. sold 40,000 shares of Galectin Therapeutics Inc. at $5.25 per share, a transaction worth $210.0K. The trade was recorded as open-market sale and disclosed on an SEC Form 4, filed 1 day after the transaction.
Footnotes
10X Fund, L.P. has direct beneficial ownership of all the securities owned by 10X Fund, L.P. 10X Capital Management, LLC, a Florida limited liability company, is the general partner of 10X Fund, L.P., a Delaware limited partnership, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P., but disclaims beneficial ownership of the reported securities except to the extent of its pecuniary interest therein. James C. Czirr is the manager of 10X Capital Management, LLC, and may be deemed to have indirect beneficial ownership of all or a portion of the securities owned directly by 10X Fund, L.P. and 10X Capital Management, LLC., but disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.